Product Images Rizatriptan Benzoate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Rizatriptan Benzoate NDC 68071-3568 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 3568 8
Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1
Figure 1 displays the estimated probability of achieving an initial headache response within 2 hours after treatment with rizatriptan benzoate or placebo. The plot is based on pooled data from 4 outpatient trials (Studies 1, 2, 3, and 4). The graph shows the probability of obtaining no or mild pain over time. The averages displayed are derived from patients in the trials who did not require additional treatment and achieved headache response within 2 hours.*
Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in P - rizatriptan fig2
Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment. This plot is based on data obtained in four placebo-controlled outpatient clinical trials (Studies 1, 2, 3, and 4). The plot shows the probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over time. The data includes patients who had a headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*
Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3
Not available.*
Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose o - rizatriptan fig4
Figure 4 shows the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 5 and 6. The graph represents the percentage of patients taking a second dose or rescue medication at different time points post dose. The data used to create the graph is obtained from two placebo-controlled outpatient clinical trials, and patients who did not use additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who did not respond to the initial dose.*
Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5
This text appears to be a figure or graph displaying the observed percentage of patients reporting no headache pain by 2 hours after taking a dose in Study 7. It seems to be comparing the effectiveness of Rizatriptan Benzoate OD Tablets versus a placebo. The graph shows percentages from 0% to 100% in increments of 10% and includes data points at various percentages. The x-axis represents the number of hours post stage 2 dose, with intervals marked at 10, 15, and 20 hours. Overall, this graph provides information on the pain relief response rate of Rizatriptan Benzoate OD Tablets compared to the placebo in Study 7.*
Chemical Structure - rizatriptan str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.